Keros Therapeutics Stock Current Valuation
| KROS Stock | USD 58.55 1.16 2.02% |
Valuation analysis of Keros Therapeutics helps investors to measure Keros Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value Over EBITDA is likely to drop to -5.89 in 2024. Enterprise Value Multiple is likely to drop to -5.89 in 2024. Fundamental drivers impacting Keros Therapeutics' valuation include:
Price Book 4.3629 | Enterprise Value 1.8 B | Enterprise Value Ebitda (13.05) | Price Sales 3.6 K | Enterprise Value Revenue 2.8 K |
Undervalued
Today
Please note that Keros Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Keros Therapeutics is based on 3 months time horizon. Increasing Keros Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Keros stock is determined by what a typical buyer is willing to pay for full or partial control of Keros Therapeutics. Since Keros Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Keros Stock. However, Keros Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 58.55 | Real 74.11 | Target 88.86 | Hype 58.2 |
The intrinsic value of Keros Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Keros Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Keros Therapeutics helps investors to forecast how Keros stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Keros Therapeutics more accurately as focusing exclusively on Keros Therapeutics' fundamentals will not take into account other important factors: Keros Therapeutics Company Current Valuation Analysis
Keros Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Keros Therapeutics Current Valuation | 1.81 B |
Most of Keros Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Keros Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Keros Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Keros Therapeutics is extremely important. It helps to project a fair market value of Keros Stock properly, considering its historical fundamentals such as Current Valuation. Since Keros Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Keros Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Keros Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Keros Current Valuation Historical Pattern
Today, most investors in Keros Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Keros Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Keros Therapeutics current valuation as a starting point in their analysis.
Keros Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Keros Therapeutics has a Current Valuation of 1.81 B. This is 87.38% lower than that of the Biotechnology sector and 60.97% lower than that of the Health Care industry. The current valuation for all United States stocks is 89.09% higher than that of the company.
Keros Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Keros Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Keros Therapeutics could also be used in its relative valuation, which is a method of valuing Keros Therapeutics by comparing valuation metrics of similar companies.Keros Therapeutics is currently under evaluation in current valuation category among its peers.
Keros Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Keros Therapeutics from analyzing Keros Therapeutics' financial statements. These drivers represent accounts that assess Keros Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Keros Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Enterprise Value | 172.6M | 828.8M | 1.1B | 946.3M | 854.1M | 545.9M |
Keros Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Keros Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Keros Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Keros Fundamentals
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (151.18) % | ||||
| Current Valuation | 1.81 B | ||||
| Shares Outstanding | 40.51 M | ||||
| Shares Owned By Insiders | 5.40 % | ||||
| Shares Owned By Institutions | 94.60 % | ||||
| Number Of Shares Shorted | 2.22 M | ||||
| Price To Book | 4.36 X | ||||
| Price To Sales | 3,643 X | ||||
| Revenue | 151 K | ||||
| Gross Profit | (87.27 M) | ||||
| EBITDA | (152.18 M) | ||||
| Net Income | (152.99 M) | ||||
| Cash And Equivalents | 215.62 M | ||||
| Cash Per Share | 8.37 X | ||||
| Total Debt | 14.44 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 14.39 X | ||||
| Book Value Per Share | 13.57 X | ||||
| Cash Flow From Operations | (124.51 M) | ||||
| Short Ratio | 5.73 X | ||||
| Earnings Per Share | (5.22) X | ||||
| Target Price | 90.69 | ||||
| Number Of Employees | 160 | ||||
| Beta | 1.24 | ||||
| Market Capitalization | 2.37 B | ||||
| Total Asset | 370.02 M | ||||
| Retained Earnings | (381.43 M) | ||||
| Working Capital | 322.92 M | ||||
| Current Asset | 11.95 M | ||||
| Current Liabilities | 5.72 M | ||||
| Net Asset | 370.02 M |
About Keros Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Keros Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Keros Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Keros Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.